# ● PRINTER RUSH ●

## (PTO ASSISTANCE)

| | | | | | |
|---|---|---|---|---|---|
| **Application :** | 09/831123 | **Examiner :** | Cook | **GAU :** | 1641 |
| **From:** | NRB | **Location:** | (IDC) FMF FDC | **Date:** | 8-2-05 |

Tracking #: 05996924-6 Week Date: 8-16-04

| DOC CODE | DOC DATE | MISCELLANEOUS |
|---|---|---|
| ☐ 1449 | | ☐ Continuing Data |
| ☐ IDS | | ☐ Foreign Priority |
| ☐ CLM | | ☐ Document Legibility |
| ☐ IIFW | | ☐ Fees |
| ☐ SRFW | | ☐ Other |
| ☑ DRW | 1-28-2004 | |
| ☐ OATH | | |
| ☐ 312 | | |
| ☐ SPEC | | |

[RUSH] **MESSAGE:** Attn.: Chief Draftsperson

Stamp covers part of the drawings.

Please Resolve.

Thank you,
NRB

[XRUSH] **RESPONSE:** Corrected Drawings
8-11-05

**INITIALS:** JC

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04

FIG. 1


START
4.803
5.239
10.159
L-APPA
10.971
D-APPA
11.504
11.997
L-CA
12.914
D-CA
15.539
16.390
L-CSA
D-ASP
L-ASP
WASH

FIG. 2


y = 0.86251 + 0.38349x R^2 = 0.999
#4
#7
y = 1.3322 + 0.23650x R^2 = 1.000
Cysteic Acid (picomoles)
Protein (micrograms)
0
1
2
3
4
5
6
7
8
0
10
20

FIG. 3


Normal
Renal
Unspecified
CAD
3.0
2.0
1.0
pmol CA/µg Protein
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Sample Number

FIG. 4


pmol CA/µg Protein
Protein (mg/100 µl)
Cholesterol (mg/ml)
VLDL
LDL
HDL
0.0
0.2
0.4
0.6
0.8
0
2
4
6
8
10
12
14
16
18
20
22
24
FPLC Fraction Number




FIG. 5A




FIG. 5B


2.0
1.5
1.0
0.5
0
Absorbance at 405 nm
1:0.5K
1:1K
1:2K
1:5K
1:10K
1:20K
Antiserum Dilution
MBP vs anti-MBP
MBP vs anti-OVA

FIG. 6

FIG. 7A


A
OVA
oxA-OVA (frac. 1)
oxA-OVA (frac. 2)
oxA-OVA (frac. 3)
Absorbance at 405 nm
2.0
1.5
1.0
0.5
0
1:200
1:500
1:1000
1:5000
Antiserum Dilution

FIG. 7B


B
PA-oxOVA
OVA (ovalbumin)
Absorbance at 405 nm
2.5
2.0
1.5
1.0
0.5
0
1:0.5K
1:2K
1:8K
1:32K
1:64K
1:256K
Antiserum Dilution

FIG. 8




HOOH oxidized HSA containing 27.9 pmol cysteic acid/μg protein
HOOH oxidized HSA containing 11.7 pmol cysteic acid/μg protein
HOOH oxidized HSA containing 4.0 pmol cysteic acid/μg protein
Unoxidized HSA

FIG. 9A


Coomassie
Mr
(kDa)
67
49
37.5
34
1 2 3 4 5 6 7 8 9 10

FIG. 9B


ECL
Mr
(kDa)
67
49
37.5
34
1 2 3 4 5 6 7 8 9 10

FIG. 10

Reactivity of mAB against PAoxBSA and unoxidized BSA




Vmax Points = 61

| Well | o F3 | □ H1 |
|---|---|---|
| Vmax | 1.091 | 749.71 |
| R^2 | 0.912 | 0.983 |

Wells coated with either 1 μg of PAoxBSA or 1 μg of unoxidized BSA.

FIG. 11

**Plate A - 96-well template**

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | 1µg K2.F1.3 | PAox K2.F1.3 | OVA + K2.F1.3 | GSA K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| B | K2.F1.1 | K2.F1.1 | .K2.F1.1 | K2.F1.1 | 1 K2.F1.3 | µg PA K2.F1.3 | ox OVA K2.F1.3 | K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| C | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.3 | 1 µg C K2.F1.3 | M-OVA K2.F1.3 | K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| D | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.3 | 1 µg K2.F1.3 | OVA K2.F1.3 | K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| E | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | 1 µg K2.F1.3 | OVA K2.F1.3 | -oxCAP K2.F1.3 | 37 K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| F | K2.F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | 1 µg K2.F1.3 | OVA-u K2.F1.3 | noxCA K2.F1.3 | P 37 K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |
| G | 1 K2.A12 | µg PA K2.A12 | ox OV K2.A12 | A K2.A12 | 1 µg K2.A12 | OVA- K2.A12 | oxCAP K2.A12 | 37 K2.A12 | K2.A12 | K2.A12 | K2.A12 | K2.A12 |
| H | K2F1.1 | K2.F1.1 | K2.F1.1 | K2.F1.1 | 1 µg K2.F1.3 | PAox K2.F1.3 | OVA + K2.F1.3 | CA K2.F1.3 | K2.F1.6 | K2.F1.6 | K2.F1.6 | K2.F1.6 |

FIG. 12A


ELISA on PAoxOVA of Normal Kids
(ages 12-16) #1-54 : Plasma at 1:200
Vmax oxOVA milliOD/min
100
90
80
70
60
50
40
30
20
10
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
Patient Number

FIG. 12B


ELISA on PAoxOVA of Normal Kids
(ages 12-16) #55-110 : Plasma at 1:200
Vmax oxOVA milliOD/min
0
10
20
30
40
50
60
70
80
90
100
55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110
Patient Number

FIG. 13


Patient Sera (1/1000)
Vmax milliOD/min
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62
Patient Number

FIG. 14


ELISA of Patient Sera (1:200) on PAoxOVA in the absence (col 1) and presence of oxOVA (col 2).
Percent Inhibition uncorrected for the blank.
Column 1
Column 2
Vmax (405 nm)
150
125
100
75
50
25
0
27%
95%
77%
62%
17%
32%
80%
94%
39%
4
10
15
23
25
26
31
47
51
Patient Number

FIG. 15


Bailey Renal Patient Plasma 1:200
Vmax milliOD/min
200
100
0
6.43
10.11
8.21
19.26
6.21
5.05
9.85
59
3.18
7.63
4.87
5.77
6.59
12.34
20.17
7
20.58
23.25
4.18
7.39
8.75
6.16
11.73
13.85
9.6
13.8
14.3
12.95
22.61
3.94
6.33
9.32
5.35
5.02
11.16
29.12
29.51
7.71
4.49
3.37
17
17.95
6.64
83.91
171.87
4.74
4.37
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
Patient Number (#48 is a 'no plasma' blank)




FIG. 16A




FIG. 16B